+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Golimumab: A novel human anti-TNF-alpha monoclonal antibody for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis



Golimumab: A novel human anti-TNF-alpha monoclonal antibody for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis



Core Evidence 4: 159-170



The introduction of tumor necrosis factor-alpha (TNF-alpha) inhibitors represented a significant advance in the management of rheumatoid arthritis (RA) and other chronic inflammatory diseases. Although three TNF-alpha inhibitors have been approved for the treatment of RA by the US Food and Drug Administration (FDA) and the European Medicinal Products Evaluation Agency (EMEA), not all patients achieve a satisfactory clinical improvement with these therapeutic agents. The mode of administration of these medications is inconvenient for some patients. Golimumab is a novel anti-TNF-alpha monoclonal antibody that is in clinical development for the treatment of RA, psoriatic arthritis (PsA), and ankylosing spondylitis (AS), either as a first-line biologic therapy or an alternative after other TNF-alpha inhibitors have been discontinued. This review summarizes the development of, and clinical evidence achieved with, golimumab. Golimumab has demonstrated significant efficacy in randomized, double-blind, placebo-controlled trials when administered subcutaneously once every four weeks. It has been generally well tolerated in clinical trials and demonstrates a safety profile comparable with currently available TNF-alpha inhibitors. Golimumab has been confirmed to be an effective treatment for patients with RA, PsA, and AS in phase III clinical trials as evaluated by traditional measures of disease activity, such as signs and symptoms, as well as measures of physical function, patient reported outcomes, and health economic measures. The efficacy and safety profile of golimumab in RA, PsA, and AS appears to be similar to other anti-TNF agents. However, golimumab has the potential advantage of once monthly subcutaneous administration and the possibility of both subcutaneous and intravenous administration.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 053433549

Download citation: RISBibTeXText

PMID: 20694072


Related references

Golimumab: A novel anti-TNF-alpha human monoclonal antibody for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. Drugs of Today 46(1): 13-22, 2010

Interferon-γ release assay versus tuberculin skin test prior to treatment with golimumab, a human anti-tumor necrosis factor antibody, in patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis. Arthritis and Rheumatism 64(7): 2068-2077, 2012

Golimumab: a new anti-TNF-alpha agent for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. Expert Review of Clinical Immunology 6(5): 721-733, 2010

AB0456Improvement and maintenance of hemoglobin levels among rheumatoid arthritis, psoriatic arthritis & ankylosing spondylitis patients with anemia of inflammation after treatment with golimumab: 3 yr pooled analysis from golimumab rheumatology clinical program. Annals of the Rheumatic Diseases 71(Suppl 3): 663.12-663, 2013

Why golimumab in the treatment of psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis?. Reumatismo 66(4): 285-303, 2015

Golimumab: in the treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Biodrugs 23(2): 125-135, 2009

The effect of golimumab on haemoglobin levels in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis. Rheumatology 52(10): 1845-1855, 2013

Immunogenicity of golimumab and its clinical relevance in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. Rheumatology 58(3): 441-446, 2019

Golimumab Utilization Patterns And Refill Adherence In Patients With Rheumatoid Arthritis, Psoriatic Arthritis And Ankylosing Spondylitis. Value in Health 17(3): A49-A50, 2014

Two-year retention rate of golimumab in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis: data from the LORHEN registry. Clinical and Experimental Rheumatology 35(5): 804-809, 2017

Five-year Safety Data from 5 Clinical Trials of Subcutaneous Golimumab in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis. Journal of Rheumatology 43(12): 2120-2130, 2016

AB1163Prevalence of Smoking and Impact on Disease Parameters Among Ankylosing Spondylitis, Rheumatoid Arthritis and Psoriatic Arthritis Patients Treated with Infliximab or Golimumab. Annals of the Rheumatic Diseases 74(Suppl 2): 1291.3-1292, 2015

Patient-reported outcomes with golimumab in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: non-interventional study GO-NICE in Germany. Rheumatology International 39(1): 131-140, 2019

FRI0175Two-Year Retention Rate of Golimumab for Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis: A Retrospective Analysis of The Italian Lorhen Registry. Annals of the Rheumatic Diseases 75(Suppl 2): 492.3-493, 2016

Introduction of biosimilar monoclonal antibodies: the changing face of rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis treatment. International Journal of Clinical Rheumatology 10(2): 61-64, 2015